SEC Form 4 · accession 0001144204-18-005239
Checkpoint Therapeutics, Inc. · CKPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James F Oliviero III
Officer — CEO and President
Period of report
Jan 30, 2018
Accepted (ET)
Feb 1, 2018 · 6:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001651407
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCK (RESTRICTED)F1,F2 | Jan 30, 2018 | A | 325,000 | $0.00 | A | 1,650,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares of restricted stock vest as follows: one-half on January 30, 2020, one-fourth on January 30, 2021 and one-fourth on January 30, 2022.
- F2Includes (a) 1,000,000 shares of restricted stock that were granted on October 13, 2015, as previously reported, and are scheduled to vest as follows: (i) 444,444 shares on October 13, 2019; (ii) 222,222 shares on the later of April 1, 2019 or the Company's achievement of market capitalization goals; and (iii) 333,334 shares on the Company's achievement of goals relating to corporate development transactions and/or FDA approval; (b) 325,000 shares of restricted stock that were granted on December 15, 2016, as previously reported, and are scheduled to vest as follows: (i) 243,750 shares on December 15, 2019; and (ii) 81,250 shares on December 15, 2020; and (c) the 325,000 shares of restricted stock that were granted on January 30, 2018, as reported herein.